Catheter Precision Appoints Former Hedge Fund Partner Philip Anderson as New CFO to Drive Growth
Catheter Precision (NYSE American:VTAK) has appointed Philip Anderson as its new Chief Financial Officer, replacing Interim CFO Margrit Thomassen, who will continue as Controller. CEO David Jenkins highlighted Anderson’s diverse background in executive management, hedge fund partnership, and investment banking.
Anderson received an inducement award of options to purchase 500,000 shares of Company common stock at $0.53 per share, vesting monthly over three years with a 10-year term. The options were granted under NYSE American listed company manual Section 711(a).
Anderson expressed enthusiasm about joining VTAK, citing the company’s position in the growing cardiac electrophysiology market, experienced management team including former Baylis and Boston Scientific executive Marie-Claude Jacques, and two revenue-generating products with strong clinical evidence.
Catheter Precision (NYSE American:VTAK) ha nominato Philip Anderson come nuovo Chief Financial Officer, sostituendo l’Interim CFO Margrit Thomassen, che continuerà come Controller. Il CEO David Jenkins ha sottolineato il background variegato di Anderson nella gestione esecutiva, nella partnership di hedge fund e nella banca d’investimento.
Anderson ha ricevuto un premio di induzione di opzioni per acquistare 500.000 azioni ordinarie della società al prezzo di $0,53 per azione, con un piano di vesting mensile da qui a tre anni e un termine di 10 anni. Le opzioni sono state concesse in base alla sezione 711(a) del manuale delle società quotate NYSE American.
Anderson ha espresso entusiasmo per l’ingresso in VTAK, citando la posizione dell’azienda nel crescente mercato dell’elettrofisiologia cardiaca, un team di gestione esperto che include l’ex dirigente di Baylis e Boston Scientific, Marie-Claude Jacques, e due prodotti generatori di fatturato con forti evidenze cliniche.
Catheter Precision (NYSE American:VTAK) ha nombrado a Philip Anderson como su nuevo Chief Financial Officer, reemplazando a la CFO interina Margrit Thomassen, quien continuará como Controladora. El CEO David Jenkins destacó el variado perfil de Anderson en la gestión ejecutiva, en la asociación de fondos de cobertura y en la banca de inversión.
Anderson recibió un premio de inducción de opciones para comprar 500,000 acciones de acciones ordinarias de la compañía a $0.53 por acción, con un período de adquisición mensual durante tres años y un plazo de 10 años. Las opciones fueron otorgadas bajo la sección 711(a) del manual de empresas listadas en NYSE American.
Anderson expresó entusiasmo por unirse a VTAK, señalando la posición de la empresa en el creciente mercado de la electrofisiología cardiaca, un equipo de gestión experimentado que incluye a la exejecutiva de Baylis y Boston Scientific, Marie-Claude Jacques, y dos productos generadores de ingresos con sólida evidencia clínica.
Catheter Precision (NYSE American:VTAK)는 Philip Anderson을 새로운 최고 재무 책임자 (CFO)로 임명했으며, 임시 CFO인 Margrit Thomassen이 계속해서 Controller로 활동할 것입니다. CEO David Jenkins는 Anderson의 경영진 관리, 헤지펀드 파트너십 및 투자 은행의 다양한 배경을 강조했습니다.
Anderson은 회사의 보통주 500,000주를 주당 $0.53에 구매할 수 있는 옵션을 받았으며, 이는 3년에 걸쳐 매달 배분되며 10년의 유효기간을 가집니다. 이 옵션은 NYSE American 상장 회사 매뉴얼 섹션 711(a) 아래에서 부여되었습니다.
Anderson은 VTAK에 합류하게 되어 흥분된 마음을 표현하며, 증가하는 심장 전기생리학 시장에서의 회사의 위치, Baylis 및 Boston Scientific의 전 임원인 Marie-Claude Jacques를 포함한 경험이 풍부한 경영진 팀, 그리고 강력한 임상 근거가 있는 두 가지 수익 창출 제품을 언급했습니다.
Catheter Precision (NYSE American:VTAK) a nommé Philip Anderson comme nouveau Chief Financial Officer, remplaçant la CFO intérimaire Margrit Thomassen, qui continuera en tant que Contrôleur. Le PDG David Jenkins a souligné le parcours diversifié d’Anderson en gestion exécutive, partenariat en fonds spéculatifs et banque d’investissement.
Anderson a reçu une prime d’incitation sous forme d’options pour acheter 500 000 actions ordinaires de la société à 0,53 $ l’action, avec un droit d’acquisition mensuel sur trois ans et une durée de 10 ans. Les options ont été accordées en vertu de la section 711(a) du manuel des sociétés cotées sur la NYSE American.
Anderson a exprimé son enthousiasme à rejoindre VTAK, citant la position de l’entreprise sur le marché croissant de l’électrophysiologie cardiaque, une équipe de direction expérimentée comprenant l’ancienne dirigeante de Baylis et Boston Scientific, Marie-Claude Jacques, et deux produits générateurs de revenus avec des preuves cliniques solides.
Catheter Precision (NYSE American:VTAK) hat Philip Anderson als neuen Chief Financial Officer ernannt und ersetzt interimistisch Margrit Thomassen, die als Controllerin weiterarbeiten wird. Der CEO David Jenkins hob Andersons vielfältigen Hintergrund in der Geschäftsführung, in Hedgefonds-Partnerschaften und im Investment Banking hervor.
Anderson erhielt einen Anreizpreis in Form von Optionen zum Kauf von 500.000 Aktien des Unternehmens zu einem Preis von 0,53 $ pro Aktie, mit monatlicher Vesting über drei Jahre und einer Laufzeit von 10 Jahren. Die Optionen wurden gemäß Abschnitt 711(a) des Handbuchs für an der NYSE American gelistete Unternehmen gewährt.
Anderson äußerte seine Begeisterung für den Eintritt in VTAK und verwies dabei auf die Position des Unternehmens im wachsenden Markt für kardiologische Elektrophysiologie, das erfahrene Managementteam, zu dem auch die ehemalige Führungskraft von Baylis und Boston Scientific, Marie-Claude Jacques, gehört, sowie auf zwei umsatzgenerierende Produkte mit solidem klinischem Nachweis.
Positive
- Strengthened executive team with experienced CFO having diverse financial background
- Company has two products already generating revenue
- Products backed by strong clinical evidence
Insights
The appointment of Philip Anderson as CFO of Catheter Precision, while a management change, carries strategic implications due to the equity compensation structure and his background. The
The company’s current market capitalization of
The electrophysiology market context is particularly relevant here. With cardiac EP being one of the fastest-growing segments in medical devices, having leadership with deep industry connections (particularly through Boston Scientific and Baylis) could accelerate market penetration. The mention of “strong clinical evidence” behind their products suggests a solid foundation for commercialization, though specific data would be needed to fully assess market potential.
David Jenkins’ track record of two previous successful startups in this field adds credibility to the venture. The combination of Marie-Claude Jacques’ sales leadership experience at major cardiac EP players and Anderson’s financial acumen could potentially accelerate the revenue ramp-up phase for their two commercial products.
FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.
David Jenkins, CEO of Catheter Precision, commented on the hire, “After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge funds at the partner level, and an early stint in investment banking. We are excited that he is joining the team immediately.”
Commenting on his new position with Catheter Precision, Mr. Anderson said, “I am thrilled to join the team at the company. What drew me to this decision was several factors. First, VTAK is in the exciting market of cardiac electrophysiology which has had tremendous growth. Secondly, the management team in place today is noteworthy. David Jenkins is an entrepreneur, and this is now his third start up in this field. Marie-Claude Jacques comes from heading up US sales at Baylis and subsequently was Vice President at Boston Scientific, Inc, also in their cardiac electrophysiology division. Third, the company has two products in the beginning of the revenue cycle, with strong clinical evidence behind the products. And finally, my skills fit directly into this company at this stage, both on the finance side as well as the operational side.”
As an inducement to Mr. Anderson’s employment, he received an award of options to purchase 500,000 shares of Company common stock. The options were granted pursuant to Section 711(a) of the NYSE American listed company manual, which provides that qualifying inducement awards may be made without obtaining shareholder approval. The options have an exercise price of
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
CONTACTS:
At the Company
David Jenkins
973-691-2000
[email protected]
# # #
View the original press release on accesswire.com
FAQ
Who is the new CFO of Catheter Precision (VTAK) and when was he appointed?
Philip Anderson was appointed as the new CFO of Catheter Precision (VTAK) on January 7, 2025.
What stock options were granted to VTAK’s new CFO as an inducement?
The new CFO received options to purchase 500,000 shares at $0.53 per share, vesting monthly over three years with a 10-year term.
How many revenue-generating products does Catheter Precision (VTAK) currently have?
According to the new CFO, Catheter Precision has two products in the beginning of the revenue cycle.
What is the current market focus of Catheter Precision (VTAK)?
Catheter Precision focuses on the cardiac electrophysiology market, developing innovative medical device products.
What happened to VTAK’s previous interim CFO Margrit Thomassen?
Margrit Thomassen, the previous interim CFO, will continue with the company in the role of Controller.
